KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Notes Payables (2016 - 2017)

Teva Pharmaceutical Industries' Notes Payables history spans 7 years, with the latest figure at $1.0 million for Q4 2017.

  • For the quarter ending Q4 2017, Notes Payables fell 93.33% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Dec 2017, down 93.33%, and an annual FY2017 reading of $1.0 million, down 93.33% over the prior year.
  • Notes Payables for Q4 2017 was $1.0 million at Teva Pharmaceutical Industries, down from $15.0 million in the prior quarter.
  • The five-year high for Notes Payables was $75.0 million in Q4 2015, with the low at $1.0 million in Q4 2017.
  • Average Notes Payables over 4 years is $34.2 million, with a median of $30.5 million recorded in 2014.
  • Year-over-year, Notes Payables skyrocketed 63.04% in 2015 and then crashed 93.33% in 2017.
  • Tracing TEVA's Notes Payables over 4 years: stood at $46.0 million in 2014, then skyrocketed by 63.04% to $75.0 million in 2015, then crashed by 80.0% to $15.0 million in 2016, then crashed by 93.33% to $1.0 million in 2017.
  • Per Business Quant, the three most recent readings for TEVA's Notes Payables are $1.0 million (Q4 2017), $15.0 million (Q4 2016), and $75.0 million (Q4 2015).